Hycor casts off urinalysis to focus on allergy and autoimmune testing
This article was originally published in Clinica
In vitro diagnostics firm Hycor has divested its urinalysis business in a bid to focus on the faster-growing allergy and autoimmune sectors. The unit, sold to a private equity consortium comprising One Rock Capital Partners, Laurel Crown Partners and StoneCreek Capital, includes Hycor's KOVA urinalysis products; the new business will be named Kova International and will be led by former Hycor executive Vance Mitchell. Financial terms were not disclosed.